BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38423221)

  • 21. Mixed neuroendocrine non-neuroendocrine neoplasm of the gallbladder complicated by a pancreaticobiliary maljunction of a non-dilated biliary duct: A case report.
    Wagatsuma K; Akita K; Motoya M; Kimura Y; Sugita S; Hirano T; Kawakami Y; Numata Y; Ishigami K; Masaki Y; Murota A; Shitani M; Akutsu N; Sasaki S; Nakase H
    Medicine (Baltimore); 2021 Oct; 100(39):e27336. PubMed ID: 34596138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.
    Choi NY; Kim BS; Oh ST; Yook JH; Kim BS
    Am Surg; 2021 Apr; 87(4):631-637. PubMed ID: 33142079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
    Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V
    Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
    Nakano M; Shimada Y; Matsumoto Y; Saiki T; Zhou Q; Sasaki K; Moriyama M; Yoshihara K; Natsumeda M; Kuriyama Y; Takii Y; Watanabe G; Umezu H; Okuda S; Ikeuchi T; Wakai T; Saijo Y
    Clin J Gastroenterol; 2022 Apr; 15(2):413-418. PubMed ID: 35133626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
    Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
    Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
    Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
    Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.
    Jesinghaus M; Konukiewitz B; Keller G; Kloor M; Steiger K; Reiche M; Penzel R; Endris V; Arsenic R; Hermann G; Stenzinger A; Weichert W; Pfarr N; Klöppel G
    Mod Pathol; 2017 Apr; 30(4):610-619. PubMed ID: 28059096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
    Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
    Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.
    Sahnane N; Furlan D; Monti M; Romualdi C; Vanoli A; Vicari E; Solcia E; Capella C; Sessa F; La Rosa S
    Endocr Relat Cancer; 2015 Feb; 22(1):35-45. PubMed ID: 25465415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China.
    Cheng Y; Zhang X; Zhou X; Xu K; Lin M; Huang Q
    Am J Cancer Res; 2022; 12(10):4737-4750. PubMed ID: 36381336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.
    Soliman ML; Tiwari A; Zhao Q
    World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.
    Mollica V; Massari F; Andrini E; Rosellini M; Marchetti A; Nuvola G; Tassinari E; Lamberti G; Campana D
    Curr Oncol; 2022 Aug; 29(8):5846-5854. PubMed ID: 36005199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
    Yamada R; Yamaguchi T; Iijima T; Wakaume R; Takao M; Koizumi K; Hishima T; Horiguchi SI
    Int J Clin Oncol; 2018 Jun; 23(3):504-513. PubMed ID: 29327160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
    Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
    Feng M; Zou J; Zhang Y; Sun L
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
    Chen L; Liu M; Zhang Y; Guo Y; Chen MH; Chen J
    Clin Colorectal Cancer; 2021 Jun; 20(2):177-185.e13. PubMed ID: 33041225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.